Product Sale

RNS Number:8121N
Tepnel Life Sciences PLC
22 July 2003



FOR IMMEDIATE RELEASE



                                                                    22 July 2003



Tepnel Life Sciences PLC ('Tepnel') Announces Second 'Nucleopure' Automated DNA
Purification System Sale


Major UK pharmaceutical company becomes repeat customer for this
advanced new system


Manchester, UK. 22 July 2003...Tepnel Life Sciences PLC (AIM: TED) announces
today that it has placed it's second Nucleopure automated DNA purification
system. The purchaser of its first new 'Nucleopure' automated DNA purification
system, formerly known as the T2000, has bought this second system. This
customer, a leading UK pharmaceutical company, will use both systems and
associated reagents for the extraction, recovery and purification of genomic DNA
from a variety of tissues and cell culture samples as part of its research into
potential new treatments for human diseases.


Tepnel has developed a pipeline of sales leads for the Nucleopure DNA extraction
system and anticipates additional placements with pharmaceutical and
biotechnology companies in the US and UK later this year. The Nucleopure is a
dedicated system that can extract DNA from 192 tissue samples in 30 minutes.
Using conventional chemistry and manual purification techniques this process
could take a skilled technician more than one week.


Commenting today, Ben Matzilevich, Tepnel's CEO, said: "The repeat purchase of
our Nucleopure system and reagents by this leading pharmaceutical company so
soon after the initial purchase is extremely encouraging. We believe it
demonstrates the value of our automated DNA purification systems to the drug
discovery process. The high throughput capabilities of the Nucleopure system are
especially important to large pharmaceutical companies, which may process
thousands of samples a month and are not willing to sacrifice either yield or
purity. Nucleopure instrument sales will generate a significant ongoing revenue
stream, given the large amounts of reagents that are consumed by this closed
system."



                                     -ends-



Further enquiries

Tepnel Life Sciences - 0161 946 2200
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Finance Director


HCC De Facto Group - 020 7496 3300
David Dible / Mark Swallow



Notes to Editors


Tepnel Life Sciences is a global biotechnology company with a "tripolar"
strategy focused on providing the biomedical industry with high-throughput
automated DNA purification systems, manual DNA purification kits and reagents,
as well as scientific services for nucleic acid purification, drug analysis,
genotyping and genetically modified foods (GMOs).


The Company was founded in 1992 to exploit DNA technology generated at UMIST
(University of Manchester Institute of Science and Technology) and is listed on
the AIM segment of the London Stock Exchange (AIM: TED).






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DISNKBKDDBKDQOB